Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial).
Barnes DJ, Dutton P, Bruland Ø, Gelderblom H, Faleti A, Bühnemann C, van Maldegem A, Johnson H, Poulton L, Love S, Tiemeier G, van Beelen E, Herbschleb K, Haddon C, Billingham L, Bradley K, Ferrari S, Palmerini E, Picci P, Dirksen U, Strauss SJ, Hogendoorn PCW, Buddingh E, Blay JY, Cleton-Jansen AM, Hassan AB. Barnes DJ, et al. Among authors: buhnemann c. BMC Cancer. 2022 Jun 8;22(1):629. doi: 10.1186/s12885-022-09697-9. BMC Cancer. 2022. PMID: 35672690 Free PMC article. Clinical Trial.
Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes.
Haley VL, Barnes DJ, Sandovici I, Constancia M, Graham CF, Pezzella F, Bühnemann C, Carter EJ, Hassan AB. Haley VL, et al. Among authors: buhnemann c. EMBO Mol Med. 2012 Aug;4(8):705-18. doi: 10.1002/emmm.201101105. Epub 2012 Jun 6. EMBO Mol Med. 2012. PMID: 22674894 Free PMC article.
Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.
Zhang YX, van Oosterwijk JG, Sicinska E, Moss S, Remillard SP, van Wezel T, Bühnemann C, Hassan AB, Demetri GD, Bovée JV, Wagner AJ. Zhang YX, et al. Among authors: buhnemann c. Clin Cancer Res. 2013 Jul 15;19(14):3796-807. doi: 10.1158/1078-0432.CCR-12-3647. Epub 2013 May 28. Clin Cancer Res. 2013. PMID: 23714727
Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma.
Varlet P, Bouffet E, Casanova M, Giangaspero F, Antonelli M, Hargrave D, Ladenstein R, Pearson A, Hawkins C, König FB, Rüschoff J, Schmauch C, Bühnemann C, Garin-Chesa P, Schweifer N, Uttenreuther-Fischer M, Gibson N, Ittrich C, Krämer N, Solca F, Stolze B, Geoerger B. Varlet P, et al. Among authors: buhnemann c. Pediatr Blood Cancer. 2022 Jan;69(1):e29316. doi: 10.1002/pbc.29316. Epub 2021 Sep 21. Pediatr Blood Cancer. 2022. PMID: 34546642
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC. Goss GD, et al. Among authors: buhnemann c. JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775. JAMA Oncol. 2018. PMID: 29902295 Free PMC article. Clinical Trial.
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A. Gadgeel S, et al. Among authors: buhnemann c. Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. Epub 2017 May 11. Lung Cancer. 2017. PMID: 28577938 Free article. Clinical Trial.
12 results